Analyzing Generex Biotechnology (OTCMKTS:GNBT) and Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Generex Biotechnology (OTCMKTS:GNBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amylyx Pharmaceuticals and Generex Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0	6	2	0	2.25
Generex Biotechnology	0	0	0	0	N/A

Amylyx Pharmaceuticals currently has a consensus target price of $17.60, indicating a potential upside of 692.79%.

Valuation & Earnings

This table compares Amylyx Pharmaceuticals and Generex Biotechnology’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$298.76 million	0.51	$49.27 million	($1.07)	-2.07
Generex Biotechnology	$2.66 million	0.00	-$33.33 million	N/A	N/A

Amylyx Pharmaceuticals has higher revenue and earnings than Generex Biotechnology.

Profitability

This table compares Amylyx Pharmaceuticals and Generex Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	-17.86%	4.14%	3.49%
Generex Biotechnology	N/A	N/A	N/A

Institutional & Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 35.2% of Generex Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Amylyx Pharmaceuticals has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, Generex Biotechnology has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.

Summary

Amylyx Pharmaceuticals beats Generex Biotechnology on 6 of the 9 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Generex Biotechnology

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.